Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03600480 · ClinicalTrials.gov registry record · Phase 1
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT03600480 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 96 participants.
The verdict
NCT03600480, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own. The study also looks at how the study medicines behave in participant's body and how they are removed from the participant's body. Participants will get 1 of the following 2 treatments - which treatment any participant gets is decided by chance: Semaglutide (a new medicine) and NNC0174-0833 (a potential new medicine), or semaglutide and placebo (a "dummy medicine similar to the study medicine but without active ingredients). Participants will get 2 injections per week for 20 weeks. A study nurse at the clinic will inject the medicine with a needle in a skin fold in the participant's stomach area. The study will last for about 16 months, but duration of participation for any participant will last up to about 7.5 months. Participants will have 28 clinic visits with the study staff and some will be overnight visits. Participants will be asked about their health, medical history and habits including mental health questionnaires.
Interventions
- DRUG Semaglutide
- DRUG NNC0174-0833
- DRUG Placebo (NNC0174-0833)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2020-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03600480
The ClinicalTrials.gov registry entry for NCT03600480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Semaglutide is the first listed.
NCT03600480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03600480 about?
NCT03600480 is a clinical study titled "A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese". The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own. The study also looks at how the study medicines behave in participant's body and how they are removed from the participa...
What is the current status of trial NCT03600480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2018-07-25. Estimated completion is 2020-06-12.
What interventions are being tested in trial NCT03600480?
The interventions under investigation include: Semaglutide (DRUG), NNC0174-0833 (DRUG), Placebo (NNC0174-0833) (DRUG).
Who is sponsoring clinical trial NCT03600480?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.